Skip to main content
Premium Trial:

Request an Annual Quote

ParAllele to Genotype Heart Disease Patients for Novartis

NEW YORK, Oct. 5 (GenomeWeb News) - ParAllele BioScience will genotype heart disease patients for Novartis Pharma, the South San Francisco-based company said today.


Under the agreement, ParAllele will discover new SNPs in candidate genes provided by Novartis, using its Mismatch Repair Detection technology. These SNPs will then be profiled across a large population of coronary artery disease patients and mateched controls to identify disease markers.


ParAllele will have the rights for diagnostic applications, while Novartis, which will pay for the study, plans to use the markers in drug discovery.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.